Yeah, but I feel like the psychedelics part is only a small part of their overall portfolio of potential products. Yes OSA is very promising but there are others - example the cannabis / whistle product for TBI was really compelling…. I’m long term bullish, but it’s a 3-5 year play. I think their 13m private capital raise in Dec was also positive. But perhaps with IHL I am a bit biased. I have a lot of conditions they are seeking to treat and participated in the PSI-GAD trial so it’s more tangible for me. Their consultant for TMJ is actually my doctor/dentist for instance and I feel like since I’m potentially the target market I bought for this reason…they have smart capable people on the team from my assessments. Usually I am a pragmatic hard nosed investor looking at the underlying fundamentals - IHL is just different so I do appreciate the more arms length perspective you are sharing. At 25k I’d expect 20m if they do 800 people per annum in AU, assuming they can get private health to cover the cost. They have 16 trained therapists who Id expect would be on payroll at 200k p.a. - my sense is revenue could be 20m less ~6m in operating costs per annum. Not bad for a single center! Are you sure it’s not commercially viable? Noting I am deeply disappointed at their pricing model and expected it to be somewhere closer to 2-5k to get a higher volume of patients in.